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As detailed in our article, we classified all adverse events using the Medical 
Dictionary for Regulatory Activities and they were further categorised by degree of 
certainty (definite, probable or possible) according to pre-specified definitions. The 
frequency of most adverse events, including all those assigned by system organ 
classification to musculo-skeletal and connective tissue disorders, was similar in both 
phases of the trial (7-9%) but, using the more specific and adjudicated definitions for 
muscle-related adverse events, the frequency was slightly lower in the non-blinded 
phase (1-2%) than the blinded phase (2%).  However, it is incorrect to assert that this 
is due to some selection bias.  For example, the statin-users in the non-blinded phase 
had similar rates of muscle-related adverse events when, during the blinded 
randomized phase, they were allocated to a statin or placebo (1.72 per 100 person-
years) or placebo (1.80 per 100 person-years; p=0.636).  Furthermore, following their 
decision of whether to continue, discontinue or commence a statin in the non-blinded 
phase, there was little difference in the reported muscle-related adverse events 
amongst those previously assigned to statin therapy (1.32 per 100 person-years), or 
placebo (1.20 per 100 person-years; p=0.500).  Indeed, the small excess in the 
reported rates amongst users who were previously assigned atorvastatin further 
strengthens our hypothesis of a ‘nocebo’ effect, as the explanation for the excess 
reporting of muscle-related adverse events in statin users during the non-blinded 
phase of the trial. 
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